AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6359846 — intervention group
Group type: EXPERIMENTAL
Intervention: pirbuterol after 3 weeks
Number of subjects: 20
Study 6359846 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 10)
Number of subjects: 20
Study 30576716 — intervention group
Group type: EXPERIMENTAL
Intervention: All-extremity high-intensity interval training (HIIT)
Number of subjects: 58
Study 30576716 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 58
Study 30576716 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CONT)
Number of subjects: 58
Study 29697876 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg/d)
Number of subjects: 63
Study 29697876 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based therapy plus pemetrexed (500 mg/m2)
Number of subjects: 63
Study 29697876 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 63
Study 29697876 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based therapy plus pemetrexed
Number of subjects: 63
Study 27492510 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 (Ang‐2) serum levels in AE‐IIPs patients
Number of subjects: 111
Study 27492510 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 (Ang‐2) serum levels in ALI/ARDS patients
Number of subjects: 111
Study 27492510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Ang‐2 levels with CRP in AE‐IIPs patients
Number of subjects: 111
Study 27492510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Ang‐2 levels with CRP and SOFA scores in ALI/ARDS patients
Number of subjects: 111
Study 27492510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang‐2 levels in survivors during treatment
Number of subjects: 111
Study 27492510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang‐2 levels in non-survivors
Number of subjects: 111
Study 22104563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic colectomy (SILC)
Number of subjects: 330
Study 22104563 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic colectomy (MLC)
Number of subjects: 330
Study 20577923 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 10 days perioperation (7 days preoperatively and 3 days postoperatively)
Number of subjects: 120
Study 20577923 — intervention group
Group type: COMPARATOR
Intervention: Non total parenteral nutrition (NTPN)
Number of subjects: 120
Study 20577923 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 120
Study 17500306 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 165
Study 17500306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 15331030 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet advertisement with rational appeal and high product involvement
Number of subjects: 120
Study 15331030 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet advertisement with emotional appeal and high product involvement
Number of subjects: 120
Study 15331030 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet advertisement with rational appeal and low product involvement
Number of subjects: 120
Study 15331030 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet advertisement with emotional appeal and low product involvement
Number of subjects: 120
Study 15331030 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 11771856 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 26
Study 11771856 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26
Study 11771856 — intervention group
Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 26
Study 9394531 — intervention group
Group type: EXPERIMENTAL
Intervention: IM 10 micrograms
Number of subjects: 359
Study 9394531 — intervention group
Group type: EXPERIMENTAL
Intervention: ID 2 micrograms
Number of subjects: 359
Study 9394531 — intervention group
Group type: COMPARATOR
Intervention: IM 20 micrograms
Number of subjects: 359
Study 7960442 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary microscopy, transcutaneous oximetry (tcpO2), and laser Doppler fluxmetry
Number of subjects: 130
Study 7960442 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxygen pressure measurements at rest
Number of subjects: 130
Study 7960442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle and toe pressure measurements
Number of subjects: 130
Study 7960442 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters and techniques
Number of subjects: 130
Study 3593896 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate controlled release (600 mg day-1 for 4 days)
Number of subjects: 24
Study 3593896 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine gluconate controlled release (600 mg day-1 for 4 days)
Number of subjects: 24
Study 3593896 — intervention group
Group type: COMPARATOR
Intervention: Quinidine sulfate extended-release (300 mg q12h)
Number of subjects: 24
Study 3593896 — intervention group
Group type: COMPARATOR
Intervention: Quinidine sulfate in solution (150 mg q6h)
Number of subjects: 24
Study 3593896 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine gluconate controlled-release (q12h)
Number of subjects: 24
Study 29158180 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral tilt-down position (LTDP)
Number of subjects: 258
Study 27443598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (0.03 g/kg/day)
Number of subjects: 116
Study 27443598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 25585502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.25% + 1 μg/kg Dex (GIII)
Number of subjects: 45
Study 25585502 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal saline (GI)
Number of subjects: 45
Study 25585502 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal bupivacaine 0.25% (GII)
Number of subjects: 45
Study 23602770 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 110
Study 23602770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily)
Number of subjects: 110
Study 20606091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus bevacizumab
Number of subjects: 602
Study 20606091 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 602
Study 19038771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin, 300 mg single oral dose
Number of subjects: 20
Study 19038771 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine, 10 mg IV
Number of subjects: 20
Study 19038771 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine, 50 mg oral dose
Number of subjects: 20
Study 19038771 — intervention group
Group type: COMPARATOR
Intervention: True placebo
Number of subjects: 20
Study 16803605 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day ranitidine bismuth citrate-based triple therapy (ranitidine bismuth citrate + amoxicillin + clarithromycin)
Number of subjects: 206
Study 16803605 — intervention group
Group type: COMPARATOR
Intervention: 4-day ranitidine bismuth citrate-based triple therapy (ranitidine bismuth citrate + amoxicillin + clarithromycin)
Number of subjects: 206
Study 12784408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (education, quadriceps and functional exercises, patellar taping) delivered in nine 30-minute sessions over 10 weeks.
Number of subjects: 87
Study 12784408 — intervention group
Group type: COMPARATOR
Intervention: Standard non-physiotherapy treatment (control group).
Number of subjects: 87
Study 10355237 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective review of photographs relating to previously experienced events
Number of subjects: 0
Study 10355237 — intervention group
Group type: COMPARATOR
Intervention: No review of photographs
Number of subjects: 0
Study 8950732 — intervention group
Group type: EXPERIMENTAL
Intervention: Leboyer method (cord clamping after 3 min)
Number of subjects: 30
Study 8950732 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (< 10s)
Number of subjects: 30
Study 1837130 — intervention group
Group type: COMPARATOR
Intervention: UW solution
Number of subjects: 0
Study 1837130 — intervention group
Group type: EXPERIMENTAL
Intervention: SLF Cochin
Number of subjects: 0
Study 6290228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CRL) 2 ng kg‐1
Number of subjects: 8
Study 6290228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CRL) 4 ng kg‐1
Number of subjects: 8
Study 6290228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6290228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CRL)
Number of subjects: 8
Study 30057908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 30
Study 30057908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal microdroplet injection
Number of subjects: 30
Study 30057908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanomicroneedle delivery
Number of subjects: 30
Study 30057908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal microdroplet group
Number of subjects: 30
Study 30057908 — intervention group
Group type: COMPARATOR
Intervention: Control group (Intramuscular injection)
Number of subjects: 30
Study 30057908 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 26842133 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered weight loss intervention
Number of subjects: 107
Study 26842133 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 107
Study 24886206 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year school-based multi-component intervention including smoke-free school premises, parental involvement, and a curricular component.
Number of subjects: 4468
Study 24886206 — intervention group
Group type: COMPARATOR
Intervention: Control group (43 schools) with no intervention specified.
Number of subjects: 4468
Study 22382596 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS
Number of subjects: 50
Study 22382596 — intervention group
Group type: COMPARATOR
Intervention: Fixed-level PS
Number of subjects: 50
Study 20592434 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (six postcards mailed over 12 months)
Number of subjects: 0
Study 20592434 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18372153 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 169
Study 18372153 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression stockings)
Number of subjects: 169
Study 15779527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low working-memory span group
Number of subjects: 0
Study 15779527 — intervention group
Group type: COMPARATOR
Intervention: High working-memory span group
Number of subjects: 0
Study 11941946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bd and Amoxicillin 1 g bd (LA)
Number of subjects: 177
Study 11941946 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bd and Amoxicillin 1 g bd (OA)
Number of subjects: 177
Study 11941946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bd, Amoxicillin 1 g bd and Clarithromycin 500 mg bd (LAC)
Number of subjects: 177
Study 9921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1.0 mg/kg every other week for five doses)
Number of subjects: 275
Study 9921806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 7573900 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolept-anaesthesia (NLA)
Number of subjects: 1318
Study 7573900 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (BAL)
Number of subjects: 1318
Study 7573900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol anaesthesia (IVA)
Number of subjects: 1318
Study 7573900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1318
Study 2304255 — intervention group
Group type: EXPERIMENTAL
Intervention: GOE anesthesia and 0.2 mg epidural Bn every three hours (group B)
Number of subjects: 63
Study 2304255 — intervention group
Group type: EXPERIMENTAL
Intervention: GOE anesthesia and 0.2 mg epidural Bn every six hours (group C)
Number of subjects: 63
Study 2304255 — intervention group
Group type: COMPARATOR
Intervention: GOE anesthesia only (group A)
Number of subjects: 63
Study 6994765 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 1.0 mg intravenously
Number of subjects: 6
Study 6994765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (25 mg and 50 mg)
Number of subjects: 8
Study 6670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (above 100 mg)
Number of subjects: 8
Study 6670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (C1Q)
Number of subjects: 8
Study 30620668 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 305
Study 30620668 — intervention group
Group type: COMPARATOR
Intervention: platinum-based chemotherapy (four to six cycles)
Number of subjects: 305
Study 30620668 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab (after crossover from chemotherapy)
Number of subjects: 305
Study 30620668 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 305
Study 30620668 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 305
Study 29754417 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching
Number of subjects: 88
Study 29754417 — intervention group
Group type: COMPARATOR
Intervention: Video PBLS lesson
Number of subjects: 88
Study 27289488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed low dose of low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 27289488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose of low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 27289488 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 24131674 — intervention group
Group type: EXPERIMENTAL
Intervention: EU paricalcitol dosing regimen (initial μg dose based on iPTH/80)
Number of subjects: 216
Study 24131674 — intervention group
Group type: COMPARATOR
Intervention: US paricalcitol dosing regimen (initial dose of 0.04 μg/kg)
Number of subjects: 216
Study 22492669 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service maintenance treatment (SMSMT) for 9 months
Number of subjects: 141
Study 22492669 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service maintenance treatment (SMSMT)
Number of subjects: 141
Study 22492669 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 19733912 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase cognitive therapy (A‐CT)
Number of subjects: 84
Study 19733912 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 84
Study 18478278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg intramuscularly (arm A)
Number of subjects: 89
Study 18478278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg orally (arm B)
Number of subjects: 89
Study 15955118 — intervention group
Group type: COMPARATOR
Intervention: Nicotine 0 mg + Caffeine 0 mg
Number of subjects: 12
Study 15955118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 1 mg + Caffeine 50 mg
Number of subjects: 12
Study 15955118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 1 mg + Caffeine 100 mg
Number of subjects: 12
Study 15955118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2 mg + Caffeine 50 mg
Number of subjects: 12
Study 15955118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2 mg + Caffeine 100 mg
Number of subjects: 12
Study 12061413 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom cognitive‐behavioral treatment (CBT)
Number of subjects: 38
Study 12061413 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based audio relaxation treatment (HART)
Number of subjects: 38
Study 12061413 — intervention group
Group type: COMPARATOR
Intervention: Delayed‐treatment control
Number of subjects: 38
Study 10067573 — intervention group
Group type: EXPERIMENTAL
Intervention: New instruments for measuring sleep patterns
Number of subjects: 0
Study 7668036 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbed DT vaccine (n = 51)
Number of subjects: 104
Study 7668036 — intervention group
Group type: COMPARATOR
Intervention: Fluid DT vaccine (n = 53)
Number of subjects: 104
Study 7668036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 104
Study 2206782 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dipyridamole
Number of subjects: 96
Study 2206782 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg acetylsalicylic acid
Number of subjects: 96
Study 2206782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole and acetylsalicylic acid
Number of subjects: 96
Study 2206782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 7192617 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (subjected to 'conflict' 2 h daily for 12 weeks)
Number of subjects: 18
Study 7192617 — intervention group
Group type: COMPARATOR
Intervention: Restraint control (placed in conditioning cages but not subjected to conflict)
Number of subjects: 18
Study 7192617 — intervention group
Group type: COMPARATOR
Intervention: Maturation control (neither restrained nor stressed)
Number of subjects: 18
Study 31034352 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill restorative RBCs (Filtek Bulk‐Fill Restorative, Tetric N Ceram Bulk‐Fill, Beautifil Bulk-fill Restorative)
Number of subjects: 30
Study 31034352 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill flowable RBCs (Filtek Bulk‐Fill Flowable, Tetric N Flow Bulk‐Fill, Beautifil Bulk-Fill Flowable)
Number of subjects: 30
Study 31034352 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning in air
Number of subjects: 30
Study 31034352 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning in ethanol
Number of subjects: 30
Study 31307254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispogel
Number of subjects: 77
Study 31307254 — intervention group
Group type: COMPARATOR
Intervention: Cathejell
Number of subjects: 77
Study 28166324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with a systolic BP target of less than 120 mm Hg (n = 1317)
Number of subjects: 2636
Study 28166324 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with a BP target of less than 140 mm Hg (n = 1319)
Number of subjects: 2636
Study 28166324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 2636
Study 28166324 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 2636
Study 26291900 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted fluid minimization (TFM)
Number of subjects: 82
Study 23612453 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg per day until progression or unacceptable toxicity
Number of subjects: 44
Study 21942502 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134
Study 21942502 — intervention group
Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134
Study 21942502 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-therapy communication changes
Number of subjects: 134
Study 21942502 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-therapy levels of problem solving and changes in wives' positivity
Number of subjects: 134
Study 21942502 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed communication improvements
Number of subjects: 134
Study 21942502 — intervention group
Group type: EXPERIMENTAL
Intervention: Positivity results
Number of subjects: 134
Study 18295441 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 100
Study 18295441 — intervention group
Group type: COMPARATOR
Intervention: Stripping
Number of subjects: 100
Study 17141087 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 40
Study 17141087 — intervention group
Group type: COMPARATOR
Intervention: Microelectrode (cutting mode)
Number of subjects: 40
Study 17141087 — intervention group
Group type: COMPARATOR
Intervention: Microelectrode (coagulation mode)
Number of subjects: 40
Study 14578410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomerizine 0.1 mg/kg
Number of subjects: 40
Study 14578410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomerizine 0.3 mg/kg
Number of subjects: 40
Study 14578410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomerizine 5 mg
Number of subjects: 40
Study 14578410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10785219 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mM glucose
Number of subjects: 0
Study 10785219 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.56 mM glucose
Number of subjects: 0
Study 9049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Strippings (1, 3, and 5)
Number of subjects: 0
Study 9049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Strippings (3)
Number of subjects: 0
Study 9049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Strippings (1 to 5)
Number of subjects: 0
Study 9049040 — intervention group
Group type: EXPERIMENTAL
Intervention: Strippings (3 and 5)
Number of subjects: 0
Study 8279682 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak ultrasonication of ethanol solutions (40 kHz, 12 mW, 1 week)
Number of subjects: 0
Study 8279682 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated aqueous ethanol solution
Number of subjects: 0
Study 8279682 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated solutions
Number of subjects: 0
Study 2881574 — intervention group
Group type: COMPARATOR
Intervention: Org 2305 15 mg (O 15)
Number of subjects: 15